Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Reduction in salivary flow Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Reduction in frequency and severity of drooling Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Adverse Effects to BoNT‐A Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Non‐compliance with intervention Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Reduction in salivary flow Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Reduction in frequency and severity of drooling Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Adverse effects of benztropine Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Adverse effects of glycopyrrolate Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Non‐compliance with intervention Interventions for drooling in children with cerebral palsy (2012) · Cochrane | no estimate extracted | NR | Low |
Intervention NR All‐cause mortality · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient satisfaction · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects 12 to 13 weeks · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Weight loss (change in kg) · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | 6 studies · 532 participants | Moderate |
Intervention NR Costs · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.95 [0.52, 1.7] | 1 study · 75 participants | Low |
Febuxostat 80 mg/day vs placebo Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 2.8 [0.72, 10.7] | 2 studies · 479 participants | Moderate |
Febuxostat 80 mg/day vs placebo Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.8 [0.74, 4.5] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day vs placebo Incidence of gout flares · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.7 [1.3, 2.3] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day vs placebo Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 80.7 [16, 405.5] | 2 studies · 356 participants | Low |
Febuxostat 120 mg/day vs placebo Pain · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Patient global assessment · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Health Related Quality of Life · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 40.1 [2.5, 639.1] | 1 study · 69 participants | Low |
Febuxostat 120 mg/day vs placebo Serious Adverse events · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 2.7 [0.7, 10.2] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day vs placebo Discontinuations due to adverse events · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.7 [0.67, 4.1] | 2 studies · 479 participants | Moderate |
Febuxostat 40 mg/day vs allopurinol Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.97 [0.57, 1.65] | 1 study · 1324 participants | High |
Febuxostat 40 mg/day vs allopurinol Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.1 [0.94, 1.2] | 1 study · 1324 participants | Moderate |
Febuxostat 40 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.61 [0.35, 1.07] | 1 study · 1513 participants | High |
Febuxostat 40 mg/day vs allopurinol Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.2 [0.9, 1.7] | 1 study · 1513 participants | High |
Febuxostat 80 mg/day vs allopurinol Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.1 [0.98, 1.3] | 3 studies · 2325 participants | High |
Febuxostat 40 mg/day vs placebo Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.8 [1.6, 2.2] | 3 studies · 2193 participants | Low |
Febuxostat 80 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.91 [0.34, 2.4] | 3 studies · 1044 participants | Moderate |
Febuxostat 80 mg/day vs allopurinol Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.3 [0.79, 2.1] | 3 studies · 1044 participants | Moderate |
Febuxostat 120 mg/day vs allopurinol Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.3 [0.87, 1.9] | 2 studies · 986 participants | High |
Febuxostat 120 mg/day vs allopurinol Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 2.2 [1.9, 2.5] | 2 studies · 880 participants | Moderate |
Febuxostat 120 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |